MannKind (MNKD)
(Real Time Quote from BATS)
$5.00 USD
+0.14 (2.88%)
Updated Jun 21, 2024 11:08 AM ET
3-Hold of 5 3
D Value A Growth D Momentum B VGM
Brokerage Reports
MannKind Corporation [MNKD]
Reports for Purchase
Showing records 41 - 60 ( 228 total )
Company: MannKind Corporation
Industry: Medical - Biomedical and Genetics
3Q18 Results; Expected Light Afrezza; Renewed Focus on Technosphere Pipeline
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: MannKind Corporation
Industry: Medical - Biomedical and Genetics
TreT Showcased at United?s Science Day; PK Data Looks Advantageous
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: MannKind Corporation
Industry: Medical - Biomedical and Genetics
Inhalable Treprostinil Partnered With Market Leader United; Brings in Non-Dilutive Cash; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: MannKind Corporation
Industry: Medical - Biomedical and Genetics
2Q18 Results; Afrezza Trending Up, But Awaiting Acceleration; Guidance Lowered; Reduce Target to $4
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: MannKind Corporation
Industry: Medical - Biomedical and Genetics
New Data and New Credibility for Afrezza at ADA
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: MannKind Corporation
Industry: Medical - Biomedical and Genetics
Treprostinil Phase 1 a Reminder of MannKind Technology Platform Potential
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: MannKind Corporation
Industry: Medical - Biomedical and Genetics
1Q18 Results; In-Line Q and Exciting Data on Tap, But We Lower Estimates on Slower Afrezza Ramp; Reduce Target to $5
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: MannKind Corporation
Industry: Medical - Biomedical and Genetics
4Q17 Results in Line; Now it?s Time to Deliver; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: MannKind Corporation
Industry: Medical - Biomedical and Genetics
Takeaways From Our Pulmonary Arterial Hypertension (PAH) KOL Dinner
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: MannKind Corporation
Industry: Medical - Biomedical and Genetics
3Q Update; With Cash in Hand, Launching DTC to Drive Demand; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: MannKind Corporation
Industry: Medical - Biomedical and Genetics
Improved Near-Term Liquidity, Afrezza Brazil Filing, and Pricing Normalization; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: MannKind Corporation
Industry: Medical - Biomedical and Genetics
A Breath of New Life With Afrezza Turnaround Story; Initiate With Buy and $7 Target
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: MannKind Corporation
Industry: Medical - Biomedical and Genetics
Company: MannKind Corporation
Industry: Medical - Biomedical and Genetics
Company: MannKind Corporation
Industry: Medical - Biomedical and Genetics
Company: MannKind Corporation
Industry: Medical - Biomedical and Genetics
Company: MannKind Corporation
Industry: Medical - Biomedical and Genetics
Company: MannKind Corporation
Industry: Medical - Biomedical and Genetics
We are suspending coverage of MannKind Corporation with this report as part of a reallocation of our resources.
Provider: Griffin Securities, Inc.
Analyst: MARKEY K